Blastomycosis | Market Size, Share & Growth Report 2024-2032
The Blastomycosis Market Report is Segmented by Product Type (Antifungal Medications, Antibiotics, Antipyretics, Analgesics, and Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Ingredient Type (Amphotericin B, Itraconazole, Fluconazole, Voriconazole, and Others).
Blastomycosis Market
Market Analysis
How the market stands today, and what is shaping it
The global blastomycosis treatment market was estimated at approximately USD 245.0 million in 2024 and is projected to reach around USD 343.67 million by 2032, representing a CAGR of approximately 4.32% during 2024–2032, based on Core Market Research estimates. Market growth is supported by the continued need for antifungal treatment in endemic areas, increasing recognition of cases, and a growing population of patients at risk of severe disease, including immunocompromised individuals. Treatment remains centered on amphotericin B for severe disease and itraconazole for longer-term therapy, following the severity-based approach established in the 2008 IDSA guidelines, with consolidation running six to twelve months. Limited disease-specific drug development, diagnostic delays and supply constraints affecting certain amphotericin B formulations remain important market challenges. The market is primarily supplied by antifungal products developed for broader systemic fungal infections rather than by therapies developed for blastomycosis, so competition occurs largely within the broader antifungal market, with treatment availability, formulation supply and cost shaping the landscape. Recent CDC-published findings from Albany Medical Center documented rising case counts after 2014, supporting the view that geographic expansion of recognised disease is becoming an important market consideration.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Laboratory-confirmed cases at Albany Medical Center were stable from 2000 to 2014 and then rose, with 2024 alone accounting for 24% of the 54 cases recorded across 2000 to 2024. An expanding endemic focus along the Mohawk River valley enlarges the population at risk and converts into diagnosed, treated cases.
- The 2008 IDSA guidelines set a severity-based algorithm. Moderately severe disease starts with lipid amphotericin B at 3 to 5 mg per kg daily for one to two weeks. Oral itraconazole then continues for six to twelve months. A defined algorithm makes prescribing consistent across treating centres.
- Amphotericin B is the only agent approved for treating blastomycosis in pregnant women and is the treatment of choice for immunocompromised patients, life-threatening disease and central nervous system involvement. Holding the sole option in those situations secures demand that no azole can displace.
- Extended treatment duration is the principal volume mechanism. Guideline therapy runs six to twelve months for most presentations, so a comparatively small number of diagnosed cases generates sustained per-patient drug consumption over most of a year.
- Gilead's liposomal amphotericin B remained unaffected by the shortage as of 12 January 2026, while conventional and lipid complex formulations went to back order. Supply continuity has become a commercial advantage in its own right, because treating centres substitute toward the formulation that is actually available.
Market Challenges
- X-Gen Pharmaceuticals is the sole United States manufacturer of conventional lyophilised amphotericin B and has had ongoing manufacturing delays with no estimated resupply date, while Leadiant's Abelcet 100 mg per 20 mL vials are on back order. Single-source supply for induction therapy exposes treatment to interruption.
- Blastomycosis is reportable to health departments in only five states: Arkansas, Louisiana, Michigan, Minnesota and Wisconsin. It is not reportable in New York, where the emerging focus was documented, so national case counts understate the treated population and obscure the size of the market.
- Nearly all cases in the Albany series were initially misdiagnosed, most commonly as pneumonia or malignancy. Misdiagnosis delays antifungal therapy, shifts spending to antibacterials that have no activity against Blastomyces, and allows progression to disease requiring intravenous induction.
- No antifungal is being developed for blastomycosis. Olorofim received a Complete Response Letter in June 2023 and targets rare moulds, and fosmanogepix holds fast track designations covering coccidioidomycosis but not blastomycosis, so this indication depends on agents developed for other infections.
- Fifty-seven percent of patients in the Albany series had no underlying condition, so risk cannot be predicted from immunosuppression as it can in other invasive mycoses. Without an identifiable at-risk group, there is no population in which prophylaxis or routine screening could be justified.
Opportunities
- Authors of the 2026 CDC study advocated that blastomycosis become reportable to state health departments. If reporting were extended beyond the current five states, measured incidence could rise substantially and give the market a documented size it does not presently have.
- Cases have been described in Vermont and New Hampshire, where 100 patients were identified at Dartmouth Hitchcock Medical Center and the University of Vermont Medical Center between 2013 and 2023. Recognition of further northeastern foci may extend the treated geography beyond the historical river basins.
- Eighty-seven percent of patients in the Albany series required hospitalisation while 13% were managed as outpatients. Earlier recognition could shift a greater share toward oral itraconazole managed in ambulatory settings, which may reduce the induction burden that the amphotericin B shortage currently constrains.
- Fosmanogepix has FDA fast track status covering coccidioidomycosis, and Basilea began a phase 3 study in invasive mould infections in July 2025. Agents advancing for other endemic and invasive mycoses could later be examined in blastomycosis, though none carries that indication today.
- Blastomyces helicus has been isolated in Colorado, Idaho, Montana, California, Nebraska, Texas and Utah, and in Alberta and Saskatchewan. Characterising species distribution outside the classical basins may identify treated populations that current endemic maps do not capture.
Trends and Insights
Key market trends shaping the industry landscape
Endemic Boundaries Are Being Redrawn
High impactMid-termDocumented blastomycosis activity is extending beyond the Mississippi and Ohio River basins into the northeastern United States, with upstate New York and northern New England now reporting sustained case series.
Insight: Case counts at Albany Medical Center were stable from 2000 to 2014 and then rose to 24% of the 25-year total in 2024 alone, so the treated population is growing through geographic extension rather than through rising incidence in established areas.
Supply Security Is Displacing Clinical Choice
High impactShort-termFormulation selection for induction therapy is increasingly governed by which amphotericin B product is available rather than by the guideline preference.
Insight: With the sole conventional manufacturer in delay and Abelcet on back order, treating centres fall back on the liposomal formulation, which is substantially more expensive and shifts the cost of an unchanged clinical pathway upward.
Diagnosis, Not Therapy, Is the Binding Step
Medium impactMid-termAttention is moving toward recognition and reporting rather than new drugs, with researchers arguing for reportable status and documenting routine initial misdiagnosis.
Insight: Nearly all Albany cases were first treated as pneumonia or malignancy, so improvements in diagnostic pathways would convert existing undetected disease into treated cases faster than any therapeutic advance could.
Rare Mycoses Depend on Broad-Spectrum Development
Medium impactLong-termThe antifungal pipeline is rebuilding around agents aimed at invasive candidiasis and mould infections, with rezafungin approved in March 2023 and olorofim and fosmanogepix in late-stage development.
Insight: None of these programmes carries a blastomycosis indication, so this market may inherit new options only where an agent developed for a larger infection is later extended, which places any benefit well beyond the forecast period.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
The supplied categories are Antifungal Medications, Antibiotics, Antipyretics, Analgesics and Others. No split of revenue by product type is published, so the categories are assessed by their role in the treatment pathway. Antifungal Medications are the only category with activity against Blastomyces and carry the entire definitive treatment, which runs six to twelve months. Antibiotics appear in this market for a diagnostic rather than a therapeutic reason: nearly all cases in the Albany series were initially misdiagnosed, most commonly as pneumonia, so antibacterials are consumed before the correct diagnosis is reached. That consumption is real but incidental, and it disappears once diagnosis improves. Antipyretics and Analgesics support symptom management during acute presentation. The categories are therefore not competing alternatives: one treats the disease, one reflects diagnostic delay, and two manage symptoms alongside definitive therapy.
Geography Analysis
Regional market analysis
North America
North America is where blastomycosis occurs and where essentially all documented activity sits. The disease is endemic to the Mississippi and Ohio River basins. Blastomyces gilchristii is geographically restricted to Canada and the northern United States, and Blastomyces helicus has been isolated in Colorado, Idaho, Montana, California, Nebraska, Texas and Utah, and in Alberta and Saskatchewan. A CDC Emerging Infectious Diseases study published on 26 February 2026 identified 54 laboratory-confirmed cases at Albany Medical Center between 2000 and 2024, stable until 2014 and then rising, with 24% of the total in 2024 alone. Ninety-six percent of those patients lived in upstate New York and 85% in Capital District counties, concentrated along the Mohawk River valley. Separately, 100 patients were identified in Vermont and New Hampshire between 2013 and 2023. Reporting is required in only five states, so measured incidence understates the true burden. No regional market size, revenue or growth figure for North America was identified in the sources reviewed for this report. The ranking rests on documented disease endemicity, since the organism is geographically restricted to this region.
Europe
Europe has no identified endemic focus for Blastomyces, and the disease is encountered as imported infection in travellers and former residents of North American endemic areas rather than as locally acquired disease. The commercial consequence is that European demand is incidental to the antifungal products themselves, which are supplied for a wide range of invasive fungal infections rather than for this indication. The agents involved are the same: amphotericin B formulations for severe disease and itraconazole for consolidation. Europe's more substantial role is in antifungal development rather than in blastomycosis treatment, with Basilea Pharmaceutica advancing fosmanogepix into a phase 3 study in invasive mould infections in July 2025. No blastomycosis-specific incidence series for the region has been identified.
Asia Pacific
Asia Pacific has no identified endemic area for blastomycosis, and no regional incidence series comparable to the North American data has been identified. The region's connection to this market runs through supply rather than through disease. Astellas Pharma, headquartered in Japan, is identified in the November 2024 United States prescribing information as managing AmBisome, the liposomal amphotericin B formulation that has remained available through the current shortage. Demand within the region itself would depend on imported cases and on diagnostic capability in centres unfamiliar with a disease that does not occur locally. Any claim about regional market size or growth would not be supported by evidence.
Latin America
Latin America has no identified endemic focus for Blastomyces dermatitidis, and the endemic mycoses documented in the region are caused by other organisms. Where blastomycosis is encountered it would be as imported disease. The diagnostic difficulty documented in North America applies with greater force here. Initial misdiagnosis as pneumonia or malignancy was near-universal in the Albany series even inside an endemic area, so recognition outside one is correspondingly harder. Treatment would rely on the same off-patent antifungals used elsewhere, with amphotericin B formulations for severe presentations and itraconazole for the extended consolidation phase. No regional incidence, reimbursement or treatment data has been identified.
Middle East & Africa
Middle East and Africa is the least documented region for this market, with no identified endemic focus and no regional case series. The practical constraints are diagnostic rather than therapeutic. Confirming blastomycosis requires culture and histopathology on specimens obtained through procedures such as bronchoscopy or biopsy, and the disease is readily mistaken for pneumonia or malignancy even where clinicians expect it. Severe disease additionally requires intravenous amphotericin B with the monitoring that entails, which restricts treatment to tertiary centres. Where those diagnostic and inpatient capabilities are limited, blastomycosis would be neither identified nor treated, so recorded demand in the region reflects diagnostic reach rather than the underlying occurrence of disease.
Competitive Landscape
Key players and market positioning analysis
Competition in the blastomycosis market is indirect, because no product is developed or marketed for this indication. Every agent used is positioned in the far larger systemic antifungal market, where blastomycosis represents incremental use of drugs whose commercial case rests on candidiasis, aspergillosis and other more common invasive mycoses. Participants divide into three cohorts. The first holds the oral consolidation phase, which accounts for most of the calendar time in a treatment course. Johnson & Johnson, through Janssen, has marketed itraconazole as Sporanox, the guideline initial treatment of choice for non-life-threatening disease outside the central nervous system and the six to twelve month consolidation agent for everyone else. The molecule is long off patent and widely genericised, so competition here runs on price and supply rather than on differentiation. The second cohort supplies the intravenous induction phase, and its competitive position is currently defined by availability rather than by clinical preference. Gilead Sciences manufactures the liposomal formulation AmBisome, which ASHP recorded as unaffected by the shortage on 12 January 2026. Astellas Pharma is identified in the November 2024 United States prescribing information as managing that product, so the two share a single franchise rather than competing over it. Leadiant Biosciences supplies amphotericin B lipid complex as Abelcet, currently on back order with no estimated release date, and X-Gen Pharmaceuticals is the sole United States manufacturer of the conventional lyophilised product and has ongoing manufacturing delays. Two of the three induction options are therefore constrained, which concentrates demand on the most expensive one. The third position is non-commercial and belongs to the guideline itself: the 2008 IDSA recommendations determine which agent is used at each severity level, and no participant markets against them. Research-stage contributors sit outside this structure, with Basilea Pharmaceutica advancing fosmanogepix and F2G developing olorofim, neither carrying a blastomycosis indication. The decisive competitive factors are supply continuity and cost rather than efficacy. Future differentiation may depend on whether any agent developed for broader invasive fungal disease is later extended to endemic mycoses, since the patient numbers here are too small to justify a dedicated development programme.
Major Players
Leading companies in the market
Industry Developments
9 recorded developments
ASHP recorded on 12 January that liposomal amphotericin B formulations were unaffected by the amphotericin B shortage, while conventional product from sole manufacturer X-Gen Pharmaceuticals remained in manufacturing delay and Leadiant's Abelcet stayed on back order.
The CDC journal Emerging Infectious Diseases published a study on 26 February concluding that upstate New York represents a new emerging endemic area for blastomycosis, and its authors advocated that the disease become reportable to state health departments.
Basilea Pharmaceutica initiated a phase 3 study of fosmanogepix in invasive mould infections in July, enrolling approximately 160 patients randomised two to one against standard of care, with completion and publication expected in 2028.
Blastomycosis cases at Albany Medical Center reached their highest recorded level, with 13 of the 54 cases identified across 2000 to 2024 occurring in that single year, marking the sharpest acceleration in the series.
The November United States prescribing information for AmBisome identified Astellas Pharma as managing the liposomal amphotericin B product manufactured by Gilead Sciences, clarifying the commercial arrangement behind the formulation least affected by subsequent supply problems.
The FDA issued a Complete Response Letter for olorofim in June, declining to approve the first agent of the orotomide class and requesting additional data, which removed the nearest prospect of a new mechanism reaching invasive fungal disease.
The FDA approved rezafungin for candidaemia and invasive candidiasis on 22 March, the first of several new antifungals to reach approval after a long period with an almost empty pipeline, though without any indication covering endemic mycoses.
A case series identified 100 patients with blastomycosis at Dartmouth Hitchcock Medical Center and the University of Vermont Medical Center over 2013 to 2023, documenting sustained disease activity in Vermont and New Hampshire outside the classical endemic basins.
The Infectious Diseases Society of America published its updated clinical practice guidelines for the management of blastomycosis, establishing the severity-based algorithm of amphotericin B induction followed by six to twelve months of oral itraconazole that remains the standard of care.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Johnson & Johnson
9.2 Gilead Sciences, Inc.
9.3 Astellas Pharma Inc.
9.4 Leadiant Biosciences, Inc.
9.5 X-Gen Pharmaceuticals, Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2024
Forecast Period: 2024 - 2032
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Johnson & Johnson, Gilead Sciences, Inc., Astellas Pharma Inc., Leadiant Biosciences, Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.